{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.73","upperLimit":"5.98","value":"2.17"},{"groupId":"OG001","lowerLimit":"1.17","upperLimit":"6.97","value":"1.81"},{"groupId":"OG002","lowerLimit":"1.25","upperLimit":"2.93","value":"1.62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Erlotinib metabolite OSI-420 plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of OSI-420 AUC0-24h (area under concentration curve from 0 to 24 hours post-dose) are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 1, 2, 4, 8, and 24 hours post-dose","title":"OSI-420 AUC0-24h","type":"SECONDARY","unitOfMeasure":"µmol·h/L"}